Pfizer criticized after its drop of Exubera leaves Nektar hanging
NEW YORK: Pfizer's work with Weber Shandwick on the drug Exubera has come to an end following the company's decision to drop the inhaled insulin product it launched just last year.
Sign in to continue
Need to activate your subscription?
Domain/Group Subscriptions
Click here >>
Individual Subscriptions
Click here >>
Need to activate your Subscription
Company Wide Subscriptions
Click here >>
UK Individual Subscribers
Click here >>